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recently been shown that the c-myc gene is translocated into an 
immunoglobulin locus in certain lymphoid neoplasms of both mice 
and men7-12. Thus, murine c-myc gene is recombined into the immu-
noglobulin heavy-chain locus in BALBIc plasmacytomas charac-
terized by t(12:15) translocations7,9-11. Likewise,in a majority of the 
many Burkitt’s lymphomas or non-Hodgkin’s lymphomas charac-
terized by t(8:14) (q24; q32) translocations, the c-myc gene is recom-
bined into the immunoglobulin heavy-chain locus8,11,12. It has gen-
erally been considered that in these and other neoplasms where 
nonrandom chromosomal translocations have been observed, c-onc 
genes are activated by the translocations13-15.
To understand the relationship between the translocation and acti-
vation of a c-myc gene we have been analysing the structure and 
expression of normal and translocated human c-myc genes. The 
results presented here demonstrate that the human immunoglobulin 
heavy-chain locus carries a transcriptional enhancer element analo-
gous to its mouse counterpart, and that this enhancer element may 
be playing a direct part in the activation of the translocated c-myc 
gene in some lymphoid neoplasms.
c-myc translocation in Manca cells
The non-Hodgkin’s lymphoma, Manca16, shows a chromosome 
translocation (t(8:14)(q24; q32) that is characteristic of many Burkitt’s
lymphomas14,15. In situ hybridization of a v-myc probe17 to Manca 
A functional immunoglobulin gene is generated somatically dur-
ing the differentiation of B lymphocytes by a set of developmentally 
regulated gene rearrangements1, The major function of these rear-
rangements is to generate a diverse set of complete immunoglobulin 
genes from a limited number of inherited gene segments.
Another important role of these rearrangements has recently 
been identified at least for the mouse immunoglobulin heavy -chain 
genes2-4. In an individual B lymphocyte and its progenies, only one of 
a few hundred copies of the variable (V) gene segments is expressed. 
This activation of a specific V gene segment results from its direct 
rearrangement into the vicinity of a transcriptional enhancer ele-
ment that is located upstream of the constant (C) region gene seg-
ments, between the joining (J) segments and the switch (S) region. 
Interestingly, the immunoglobulin gene-associated enhancer func-
tions in a tissue specific manner, suggesting a more general involve-
ment of cellular .enhancer elements in tissue-specific expression of 
eukaryotic genes during cell differentiation.
Another biological process in which gene rearrangements and 
enhancer elements may play a critical, albeit adventitious, role is 
tumorigenesis. A model supporting this notion comes from the stud-
ies on the chicken leukaemogenesis induced by the non-acute avian 
leukosis virus (ALV). By integrating close to the cellular oncogene, 
c-myc, the ALV provirus via its transcriptional promoter or enhancer 
element can lead to increased levels of c-myc transcription5,6. It has 
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Manca cells with that of the unrearranged allele; with a probe spe-
cific for exon I no transcription of the unrearranged c-myc gene can 
be detected in Manca cells (K.W. et al., manuscript in preparation). 
Therefore, the high c-myc level of transcription in Manca cells all 
derives from the translocated allele.
The initiation points of c-myc transcripts in Manca cells were 
mapped by S1 nuclease protection experiments23,24. using the probes 
shown at the bottom of Figure 2. The major initiation site (site 1; 
see Figure 2) for c-myc transcripts occurs about 636 base pairs (bp) 
upstream of c-myc exon II, within what would ordinarily be intron I 
of the c-myc gene. The nucleotide numbering system used to denote 
the initiation points is that of Colby et al.25, whose sequence begins 
within intron I of the human c-myc gene such that nucleotide 1,000 
defines the start of exon II. Transcripts initiating at site I (nucleotide 
364) form S1-resistant hybrids with probes b and a of 66 base pairs 
(bp) and 359 bp respectively (Figure 2B, C). Downstream of site I, 
at nucleotide 378, is a weaker initiation point, Ia (Figure 2B, C). As 
has been previously noted25, upstream of initiation sites I and Ia are 
sequences related to the consensus TATA box26,27 commonly found 
5’ of genes transcribed by RNA polymerase II (see Figure 3). Initiat-
ing at around nucleotide 873 are further transcripts, which form S1 
nuclease-resistant hybrids of length 192 bp with probe d (data not 
shown), and 28 bp upstream of this site occurs the sequence TTTATT 
(Figure 3). In addition to these initiation sites, an S1 sensitive site (X) 
in hybrids between Manca RNA and either probe a or c is detected 
at around nucleotide 520. However, the assignment of an initiation 
site to this position is uncertain, an S1-sensitive site also being appar-
ent at this position in hybrids between probes a or c and yeast RNA 
on long exposures.
If transcripts initiating at these sites were to have no functional 
splice sites 5’ of the junction between exon II and the following 
intron, then the processed RNAs would range in size from 1,660 to 
2,450 nucleotides (not including the poly(A) tail28). That this is the 
case is suggested by cDNA cloning, which has revealed a contiguous 
transcript extending upstream from exon II at least as far as position 
660. Beyond this point the S1 nuclease-sensitive sites have been con-
firmed as initiation (as opposed to splice) sites by primer extension 
analyses. For example, reverse transcripts of Manca cell RNA using 
the primer shown in Figure 2B extend as far as nucleotide 364. Fur-
ther primer extensions (for example using S1 probe b) indicate no ini-
tiation sites upstream of those characterized here (data not shown).
chromosomes indicates that the human c-myc locus is on that por-
tion of chromosome 812,18 that is translocated (data not shown).
From a cosmid library19 of Manca DNA a clone, cU23 was isolated 
that hybridized both to v-myc and to pH18-C1-10, a plasmid contain-
ing the immunoglobulin heavy-chain Cμ gene and sequences imme-
diately 5’ to it20. Southern blot analysis21 of Manca DNA indicated 
that the linkage of c-myc and immunoglobulin heavy-chain gene 
sequences detected in cU23 had occurred in the human cells, and 
not upon cloning (data not shown). A detailed map of clone cU23 
in the region of c-myc-Cμ linkage was derived by restriction analysis 
and DNA sequencing (K. W. et al., manuscript in preparation), and 
was compared with maps of human germ-line Cμ and c-myc genes, 
contained on plasmid pH18-C1-10 and cosmid cAIDS4 respectively 
(Figure 1). The latter clone was described previously22. It can be 
deduced that in Manca DNA, the human c-myc gene is fused head-
to-head with the Cμ gene, about 6.5 kilobases (kb) 5’ to the first Cμ 
exon. The junction on chromosome 14 lies between Sμ and JH6, at a 
point that is not normally used for the productive rearrangement of 
an immunoglobulin heavy chain gene. The junction on chromosome 
8 occurs between exons I and II of the c-myc gene. As a result, the 
Manca DNA cloned in cU23 contains neither exon I nor the normal 
transcriptional start sites22 of the human c-myc gene. Instead, c-myc 
exons II and III are fused to Cμ sequences that include a stretch of 
DNA between Sμ and JH that is in an analogous location to sequences 
in the mouse genome shown to have tissue-specific transcriptional 
enhancing activity2-4 (region ‘E’ in Figure 1). The translation of tran-
scripts of the human c-myc gene begins within exon II, at an initi-
ation AUG codon that is retained, and presumably used, in tran-
scripts of the translocated c-myc gene in Manca cells.
Multiple transcription initiation sites
Northern blot analysis of RNA from Manca cells indicates a high 
level of c-myc transcription (Figure 2A). It is clear that there are mul-
tiple transcripts hybridizing to the c-myc Northern probe 1 (see Fig-
ure 1). The level of c-myc transcription in Manca cells is the highest 
that we have detected in any cell line (which include other Burkitt’s 
lymphomas, and Epstein-Barr virus immortalized Iymphoblastoid 
cells) except the promyclocytic leukaemia cell line HL60 (data not 
shown). The relevance of this comparison is unclear, however, as 
all these cells are growth transformed. An alternative approach is to 
compare the level of transcription of the rearranged c-myc gene in
Figure 1, A comparison of the human 
c-myc gene and the Cμ region of the 
human immunoglobulin heavy-
chain locus to the Cμ-c-myc joining 
region of the 14:8 translocated chro-
mosome from Manca cells. Exons 
are shown as solid boxes; chro-
mosome 14 sequences as a double 
line; and chromosome 8 sequences 
as a single line. R indicates the site 
of recombination between the two 
chromosomes. E is a transcriptional 
enhancer element, which was previ-
ously identified for the mouse immu-
noglobulin heavy-chain locus2-4 
and the identification of the human 
equivalent is reported here. Sμ, Cμ 
switch sequences; Jμ, joining seg-
ments. The Jμ segments are defined 
on the basis of data presented in ref-
erence 40, and our own sequenc-
ing41. The horizontal arrows indicate
the initiation sites and directions of transcription.  Restriction sites: RI, EcoRI; X, XbaI; H, HindIII; Av, AvaI; Rs, RsaI; P, PstI; B, BglII; C, ClaI; A, AluI (the complete 
map is only shown for the first three of these). 1 and 2 delineate the extent of the probes used in the Northern blot experiments. The cloning of the recombination 
region of the translocated chromosome into cosmid pTCF19 will be described elsewhere (K.W. et al., manuscript in preparation). The unrearranged c-myc gene was 
also cloned into a cosmid. Colonies were screened with the Northern probe 1. The definition of the c-myc gene will be described22.
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Figure 2, A, Northern blot analysis42 using the probe 1 shown in Figure 1 of 
mRNA from: lane H, HeLa cells (1 μg); lane M, Manca cells (0.3 μg). B, Lanes 
1 and 2 show a primer extension analysis43, and lanes 3 and 4 an S1 nuclease 
mapping analysis23,24 of: lanes 1 and 3, Manca cell mRNA; lanes 2 and 4, yeast 
mRNA. The probes used are ‘a’ and ‘primer’ shown in the diagram below the 
photograph of the blot, and were strand separated and end labelled41 before 
hybridization. The nucleotide numbering system derives from reference 25, 
and starts (nucleotide 1) at the XbaI site in intron I of the human c-myc gene. 
Sites 1 and 1a are referred to in the text; site 1 centers on nucleotide 364, and 
the mark indicating this position on the right of the figure shows the corre-
spondence between the primer extension and S1 signals in lanes 1 and 3. Lane 
5 is a pyrimidine analysis41 of the sense strand of the probes, from which the 
nucleotide positions of the DNA-RNA discontinuity could be determined (see 
Figure 3). C, S1 nuclease analysis using the probe ‘b’ shownin the diagram 
below B of mRNA from: lane 1, Manca cells; lane 2, yeast cells. Lane 3 is the 
same type of reaction as shown in lane 5 of B, but using probe b.
Methods: The S1 nuclease reactions contained either 100 ng Manca cell mRNA 
plus 20 μg yeast RNA, or only the yeast RNA. For the S1 analysis 5 x 104 c.p.m. 
of probe was used per reaction, and for the primer extension analysis 2 x 104 
c.p.m.of probe was used per reaction. The probes were annealed to the RNA 
at 53°C for 4 h (except in the case of probe b, which was annealed at 30°C for 
12-16 h). S1 reactions were performed at 15°C for 3 h, and primer extension 
reactions at 41°C for 45 min. A 6% acrylamide gel was used for B, and run for 
7 h, and an 8% gel run for 3 h for C.
These transformation experiments strongly suggest that the 2.2 
kb human XbaI fragment contains a tissue-specific transcriptional 
enhancer element. To demonstrate this point more directly we 
examined the effect of this DNA fragment on the transcription of a 
mouse immunoglobulin γ2b gene. The plasmid pSV . γ2bΔX2/4 con-
tains a functionally rearranged mouse γ2b gene from which most of 
the sequences (including the enhancer element) between V-D-J and 
C exons have been deleted2. The plasmid also contains the select-
able Ecogpt gene. J558L cells transformed to mycophenolic acid resis-
tance by pSV . γ2bΔX2/4 express almost no γ2b heavy-chain RNA2. A 
high level of γ2b expression can be restored by re-insertion (either 
upstream or downstream of the V-D-J promoter) into plasmid pSV 
· γ2bΔX2/4 of the mouse enhancer2, and similarly by insertion of the 
human XbaI fragment (Figure 4). In this experiment, pools of cells 
transformed to a gpt+ phenotype by pSV · γ2bΔX2/4 and its derivatives 
were assayed for γ2b gene expression by S1 nuclease protection. The 
mouse enhancer was equally effective whether inserted upstream or 
downstream of the γ2b V-D-J promoter. By contrast the level of the 
γ2b gene transcription attained by the human enhancer was some-
what variable depending on its position, the highest level of expres-
sion being obtained when the enhancer was inserted upstream of the 
promoter in the opposite orientation to the direction of transcription 
(Figure 4). Interestingly, the relative orientations of enhancer and 
promoter in this case are equivalent to those of the enhancer and the 
altered c-myc promoters in Manca cell DNA (see Figure 1).
The nucleotide sequence of a portion of the JH-Cμ region of the 
human germ-line clone pH18-CL-10 was determined and compared 
with that of the corresponding region of mouse DNA (Figure 5), 
which contains the enhancer core sequences30 which are common 
to enhancers so far defined. Core-like sequences are present in the 
human DNA: there is a 67% matching between the 140 bp of mouse 
DNA that contains most, if not all, of the murine enhancing activity 
and the corresponding human sequence. The similarity between the 
mouse and human sequences throughout the region shown in Fig-
ure 5 is sufficiently strong to allow a unique alignment, with several 
insertions and deletions.
Activation of c-myc transcription
To begin to investigate whether the high level of c-myc transcription 
in Manca cells was due to proximity to the immunoglobulin heavy-
Transcriptional enhancer element
We have previously shown that sequences derived from the JH-Cμ 
region of the mouse immunoglobulin heavy-chain locus contain a 
DNA element that enhances the transcription of the associated gene 
in a manner largely independent of both position and orientation2. 
The translocation of the c-myc gene in Manca cell DNA just 300 bp 
downstream of the human JH cluster (Figure 1) suggested that the 
high level of c-myc transcription in Manca cells (Figure 2A) might be 
due to a human enhancer element located in an analogous region to 
that in the mouse (‘E’ in Figure 1).
To test this hypothesis, we first attempted to identify the putative 
human enhancer element. For this purpose, the 2.2 kilobase (kb) XbaI 
fragment (see Figure 1) containing most of the sequence between 
the JH cluster and Sμ, plus about 330 bp derived from the 5’ flank-
ing region of the translocated, truncated c-myc gene, was inserted 
into the EcoRI site of plasmid pSER2. This plasmid was derived from 
pSV2.gpt29 (which contains the mycophenolic acid-resistance confer-
ring gene Ecogpt) by deletion from the latter of the SV40 enhancer 
sequences. As a result, pSER transforms cells to mycophenolic acid 
resistance (gpt+ phenotype) at a much lower frequency than does 
pSV2.gpt (see Table 1). The original level of transformation can be 
restored by the insertion into the EcoRI site of pSER of the mouse 
immunoglobulin heavy-chain locus enhancer element2. As shown in 
Table 1, the insertion in either orientation of the human XbaI frag-
ment into the EcoRI site of pSER (2.3 kb upstream of the Ecogpt gene) 
restored the gpt+ transformation efficiency to a level even exceeding 
(by about eightfold) that of pSV2 gpt. The transformation efficiency 
of pSV2 gpt was itself increased 5-10-fold by insertion of the XbaI 
into its EcoRI site. Other fragments of mouse and human immuno-
globulin heavy-chain loci DNA had no significant effects on trans-
formation frequencies when inserted into pSER of pSV2.gpt. Also, 
like its murine counterpart the effect of the XbaI fragment was tis-
sue-specific: with rodent fibroblasts the transformation efficiencies 
of pSERXa and pSERXb were over 100 times lower that of pSV2.gpt. 
In a further experiment the 2.2 kb XbaI fragment was dissected by 
cleavage with AluI, and some of the resulting fragments also tested 
in the pSER assay. Most, if not all the enhancing activity could be 
attributed to the 279 bp fragment, Alua (delineated by the two AluI 
sites flanking the BglI site shown in the expanded map of the human 
Cμ gene in Figure 1).
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Table 1    Transformation efficiency of pSV2.gpt and derivative
        plasmids
                    Frequency of transformation to gpt+
    phenotype
      Plasmid   J558L cells*  rat-2 cells†
  pSV2.gpt       1 x 10-4       5 x 10-3
  pSV2.gpt.Xa‡      6 x 10-4          ND
  pSER       5 x 10-6          ND
  pSER.Xa‡       8 x 10-4        1 x 10-5
  pSERXb‡        8 x 10-4        1 x 10-5
  pSER.Ra§       8 x 10-6           ND
  pSER.Alu.a║      2 x 10-4          ND
  pSERAlu·z║      5 x 10-6           ND
Escherichia coli cells containing the above-mentioned plasmids were con-
verted to spheroplasts39, and fused2 to recipient cells (1010 spheroplasts per 2 x 
106 cells), after which the cells were plated at 5 x 103 (J558L) cells per well or 1 
x 105 (rat-2) cells per culture dish. The selective medium, which contained xan-
thine (250 μg ml-1), hypoxanthine (15 μg ml-1) and mycophenolic acid (6.5 μg 
ml-1), was added 48 h after fusion, and colonies were counted after 14 days. 
The experiments were routinely repeated three times. ND, not done.
*A mouse plasmacytoma cell line.
† A rodent fibroblast cell line.
‡ Xa/Xb plasmids contain an insertion in either orientation (a or b) of the 2.2 
kb XbaI fragment from cU23.
§ pSER.Ra contains an insertion of a 4 kb EcoRI fragment from the mouse 
immunoglobulin heavy-chain Cα gene.║ Alu.a/Alu.z plasmids contain an 
insertion of either of two AluI fragments (a and z) derived from the 2.2 kb 
XbaI fragment.
integration has occurred within the 11.7kb EcoRI fragment, so that 
EcoRI fragments smaller than 11.7 kb are detected with the c-myc 
probe31. Analysis with enzymes that cut within this fragment, how-
ever, indicate that in at least four out of nine cases (clones 26.1. 26.2, 
26.4 and 26.7) contiguous DNA sequences that extend from the 
enhancer through the transcriptional initiation sites mapped above, 
and into the truncated c-myc gene, are intact (Figure 6).
By contrast, the cells transformed in identical conditions by pSV2.
Δ4, contain multiple, tandem copies of the exogenous DNA, and 
in each case the c-myc transcription unit and upstream sequences 
are intact. This difference in copy number of transforming DNA 
in cells selected for gpt+ phenotype may be due to a positive effect 
(from over 7 kb away) of the enhancer on Ecogpt transcription: in 
the absence of the enhancer, high levels of Ecogpt transcription may 
only be obtained from an increased copy number. Consistent with 
this, the transformation frequency of J558L cells by pSV2Δ4 is 5-10-
fold lower than the frequency of transformation by pSV2.26 (data 
not shown). The difference in copy number may also result from a 
deleterious effect of excess c-myc gene product on J558 cells, which 
already contain an actively transcribed translocated mouse c-myc 
gene32. If such an effect exists, and if the immunoglobulin heavy-
chain locus enhancer does activate Manca cell c-myc transcription, 
then there may be a selective advantage to cells transformed with 
pSV2.26 that retain only one or even no intact copies of the Manca 
cell c-myc gene.
Both total and poly(A)+ RNA were isolated from groups of trans-
formants, and were analysed by Northern transfer and hybridiza-
tion to probe 1 (see Figure 1). Although transformants receiving 
pSV2.Δ4contained multiple intact copies of the transfected c-myc 
gene, none of them showed evidence for much c-myc transcription 
over and above the level of the mouse c-myc transcription endoge-
nous to J558L cells (data not shown). By contrast several lines of cells 
transformed by pSV2.26 showed strongly hybridizing c-myc tran-
scripts (data not shown).
Because of the variability in retention of c-myc DNA sequences, 
and the cross-reactivity of the Northern probe with the mouse c-myc 
transcripts in J558L cells, a quantitative comparison of human trans-
Figure 3, Shows the nucleotide sequence from intron I of the germ line c-myc 
gene that contains the initiation sites of the transcripts of the translocated 
c-myc gene. The recombination site of the translocated Manca chromosome 
is 336 nucleotides 5’ of the start of the sequence shown. Exon II of the germ-
line c-myc gene starts at nucleotide 1,000. The transcription initiation sites (1, 
1a and 2), as deduced by S1 and primer extension analyses, are marked by 
the thick arrows. The probes used in these analyses (a-d, a and b being those 
used in Figure 2) are shown near the top of the figure. The asterisks mark the 
32P-labelled ends of the probes. Underlined sequences are similar to those com-
monly found 5’ of RNA polymerase II-transcribed genes27. The initiator ATG 
codon of the protein encoded by c-myc is also underlined. X is an S1-sensitive 
site, and R the recombination site. The sequence data derive from reference 25 
plus our own data in the regions of designated promoters.
chain locus enhancer, the transcription of the translocated c-myc gene 
was studied in a murine mycloma cell line, J558L. The mycloma cells 
were transformed by spheroplast fusion with either of two plasmids, 
pSV.26 or pSV2.Δ4. Plasmid pSV2.26 contains the 11.7 kb EcoRI frag-
ment from cU23 (containing the translocated c-myc gene plus about 
8 kb of 5’ flanking sequences which include the immunoglobulin 
heavy-chain locus enhancer, see Figure 1) the translocated c-myc 
gene cloned into the EcoRI site of pSV2gpt. Plasmid pSV2Δ4 contains 
a 9.5 kb EcoRI fragment (derived from the 11.7 kb EcoRI fragment 
of cU23 by deletion of the central 2.2 kb XbaI fragment) cloned into 
the EcoRI site of pSV2.gpt. Plasmid pSV2Δ4 thus lacks the sequences 
identified above as having transcriptional enhancing activity.
After transforming with these plasmids, gpt+ transformants of 
J558L cells were isolated and assessed for the presence of exogenous 
DNA. Clones 26.1-26.9 were nine cloned isolates of cells transformed 
by pSV2.26; Δ4.2 is a cell line developed after transformation with 
pSV2.Δ4; Δ4.1 is a pool of several colonies transformed by pSV2.Δ4. 
Most cells transformed by pSV2.26 have acquired only single or a 
few copies of the exogenous DNA, and in most of these cases the
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(Figure 6). It cannot be argued that in either of these cases the trans-
forming DNA has become sequestered in a transcriptionally inac-
tive area, since continual selection for Ecogpt gene activity is made. 
In addition, several isolates of both total and poly(A)+ RNA from 
these cells gave the same result, and these RNAs were positive in an 
S1 nuclease protection assay of Ecogpt transcripts (data not shown). It 
appears then, that the activity of the major transcriptional initiation 
site for translocated c-myc gene transcription is severely reduced by 
deletion of sequences 360 bp upstream of it. Deletions at this dis-
located c-myc gene transcription was better made by S1 nuclease 
mapping. The S1 probe a (Figure 3), which detects the major initi-
ation site, was protected to a similar quantitative degree by Manca 
cell RNA and by RNA of several lines transformed by pSV2.26 (for 
example, lines 26.1, 26.4 and 26.7, see Figure 7). That RNA in these 
cell lines is qualitatively the same as in Manca cells was further indi-
cated by use of S1 probe b. Use of either probe shows almost no pro-
tection by RNA of cell lines Δ4.1 or Δ4.2 (see Figure 7) even though 
these cells contain multiple intact copies of the transforming DNA 
Figure 4, a, Strategy of the S1 nucle-
ase mapping experiment shown in 
c. The probe is an end-labelled Hin-
dIII-BstNI fragment, which was 
strand separated and annealed to 
total cell mRNA before S1 diges-
tion and electrophoretic resolu-
tion, which were carried out as 
described previously23,24. The 40 
bp fragment protected by correctly 
initiated γ26 mRNA is as predicted 
by primer extension analysis44. The 
solid  blocks indicate the leader 
(L) exon and 5’ end of the V-D-J 
exons. b Shows the derivatives of 
pSV.γ2bΔX2/4 used for transfec-
tion. The 2.2 kb XbaI fragment into 
the X1 (M1 and M2) or X2/4 (M3) 
sites2 in the indicated orientations. 
C Shows the S1 nuclease resistant 
hybrids formed between the probe 
shown in a and: lane 1, 20 μg tRNA; 
lane 2, 20 μg RNA from J558L cells; 
lanes 3-7, 20 μg RNA from J558L 
cells transfected with: lane 3, pSV.
γ2bVC2; lane 4, pSV.γ2bΔX2/4; lane 
5, pSV.γ2bΔX2/4 M1; lane 6, pSV.
γ2bΔX2/4 M2; lane 7, pSV.γ2bΔX2/4 
M3. In the two right-hand lanes 
are co-electrophoresed sequenc-
ing reactions34 of the probe, which 
allow the identification of the tran-
scription initiation site (arrow) and 
the GATAA box at position -30.
Figure 5, Sequences of the murine2 and human enhancer elements, which were compared using the SEQ computer program45.
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Figure 6, Southern blot analyses of c-myc containing sequences in J558L cells, 
and in their derivatives transformed with either pSV2.26 or pSV2Δ4. a Shows 
a blot obtained using probe 1 (as indicated in the diagram below) and Hin-
dIII plus EcoRI digested DNA from: lane 1, Δ4.2 cells; lane 2, Δ4.1 cells; lane 
3, J558L cells; lane 4, 26.7 cells; lane 5, 26.2 cells; lane 6, 26.1 cells; lane 7, 5 pg 
of pSV2.26 cleaved with HindIII plus EcoRI, co-electrophoresed as a marker, b 
Shows a blot obtained using probe 3 and BglII plus EcoRI cleaved DNA from: 
lane 1, 26.1 cells; lane 2, 26.5 cells; lane 3, 26.4 cells; lane 4, J558L cells; lane 5, 
as in lane 7 of a, but cut with BglII. The diagram below the blots shows the 11.7 
kb EcoRI fragment contained in pSV2.26 and also the position of the 6.5 kb 
HindIII-EcoRI fragment. The deletion (Δ) in pSV2Δ4 removes the HindIII site, 
as a result of which a 9.6 kb EcoRI fragment is the HindIII plus EcoRI digestion 
product that hybridizes to the c-myc probe. As a further result of this deletion 
the 3.1 kb BglII fragment detected with probe 3 (indicated in b) is only detected 
in pSV2.26 transformants. Bands labelled J in a are due to the cross-reactivity 
of probe 1 with normal and rear ranged mouse c-myc genes in J558L cells11,32. 
Restriction sites marked in the lower diagram: R, EcoRI; X, XbaI; H, HindIII; B, 
BglII; A, AvaI; C, ClaI.
Figure 7, S1 nuclease analysis of mRNA from Manca cells, J558L cells, and transformed derivatives of J558L cells. Lanes 1-8 were reactions involving probe a, and 
lanes 9-15 involved probe b. Lane 2 is a pyrimidine sequencing reaction of probe a, and lane 12 is a similar reaction with probe b. The other lanes are the S1 reactions, 
with mRNA from: lane 1, 26.7 cells; lane 3, J558L cells; lane 4, 26.1 cells; lane 5, 26.4 cells; lane 6, Manca cells; lane 7, Δ4.1 cells; lane 8, yeast cells; lane 9, Manca cells; 
lane 10, 26.3 cells (which retained no human c-myc sequences); lane 11, Δ4.1 cells; lane 13, 26.1 cells; lane 14, Δ4.2 cells; lane 15, J558L cells. The end-labelled, strand-
separated41 probes were melted at 85°C, then annealed to the RNAs at 51°C for probe a, and at 30 °C for 12 h for probe b. S1 digestions were carried out at 15°C for 
2 h. Electrophoresis was carried out as described previously, for lanes 1-8 on a 6% gel run for 7 h, for lanes 9-15 on an 8% gel run for 3 h. All reactions contained equal 
amounts of sample RNA made up to 20 μg with yeast RNA. S1 nuclease-sensitive sites specific for the presence of lymphoid RNA are indicated.
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and which may be a considerable distance from the translocated 
c-myc gene.
Alternatively, translocated c-myc genes may not be directly depen-
dent upon immunoglobulin sequences for their transcription, but 
rather their transcription may be activated by the accumulation 
of mutations in regulatory regions. For example, it has been sug-
gested34 that the c-myc gene product itself may regulate its own tran-
scription, and that, in lymphomas harboring translocated genes, the 
translocated but not the normal c-myc gene, escapes this repression. 
At this stage, the hypothesis of positive activation, and that of escap-
ing repression, are not mutually exclusive.
The detachment of c-myc exon I sequences from c-myc exons II and 
III is a consequence for all BALB/c and for several hutnan c-myc 
translocations thus far documented7,l0-l2,38. We have previously sug-
gested22,31 that this event, in itself, leads to increased translation of 
c-myc RNA in cells harboring such translocations.
In summary, there are probably multiple steps in the activation 
of the human c-myc gene in non-Hodgkin’s lymphomas. From this 
article it is clear that previously cryptic promoters of the c-myc gene 
are activated upon translocation, and that this activation is depen-
dent upon upstream sequences. In Manca cells, the critical element 
in these upstream sequences may be the human immunoglobulin 
heavy-chain locus enhancer element. As both the translocated c-myc 
gene from a mouse plasmacytoma and the translocated human 
c-myc gene from Manca cells have detectable biological activity (ref-
erence 46 and our unpublished data) it is apparent that the activation 
of the c-myc gene contributes to either initiation or maintenance of 
oncogenesis. It is possible that the misuse of a developmentally reg-
ulated,  cellular enhancer element will be found, in many cases, to be 
responsible for activating oncogenes.
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tance upstream of a promoter are characteristic of enhancer muta-
tions33. As the enhancing activity of the deleted fragment has been 
demonstrated and largely localized to one fragment (the Alu ‘a’ frag-
ment), it appears likely that it is the removal of the immunoglobulin 
heavy-chain locus enhancer that has drastically reduced transcrip-
tion of the translocated c-myc gene.
Multiple mechanisms of c-myc activation
We show here that Manca cells contain a translocated c-myc gene 
that is transcribed from previously cryptic start sites that ordinar-
ily form part of intron I of the c-myc gene. This transcription is 
reproduced with fidelity after introduction of the gene into mouse 
mycloma cells. Use of this system has allowed us to demonstrate 
that transcription from at least the major cryptic promoter is dramat-
ically dependent on the presence of sequen ces over 350 bp upstream 
of the RNA initiation site. These sequences include an element that 
we demonstrate to be a human immunoglobulin gene-associated 
enhancer element, and it may be this element itself that is respon-
sible for activating translocated c-myc transcription in Manca cells. 
The remaining possibility, that it was the removal of other sequences 
(including about 300 bp of DNA that are also ordinarily part of c-myc 
intron I) that drastically reduced transcription from initiation site I 
is presently being investigated. The unrearranged c-myc gene is 
still present in Manca cells, but our preliminary results from use of 
Northern probes (probe 2 in Figure 1), S1 mapping and cDNA clon-
ing indicate that this allele is barely, if at all, expressed. Such a situa-
tion has already been reported for a mouse plasmacytoma and may 
be true for other Burkitt’s lymphomas11,32,34. Hence, transcriptional 
activation of the c myc gene appears to be an important result of 
translocation and in the case described here, it is possible that such 
activation is largely contributed to by the immunoglobulin heavy-
chain locus enhancer.
The retention of the immunoglobulin associated enhancer ele-
ment adjacent to the translocated c-myc gene is not a com mon fea-
ture of c-myc translocations so far documented in either mouse7,10,11,35 
or man12,36. In these instances, the translocated gene is still tran-
scribed7,10,11,37, whilst again the untranslocated gene may be silent11,32,34. 
In these cases, transcription of the translocated c-myc gene may be 
maintained by a cellular enhancer-type element yet to be identified, 
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